Bjorn L Millard

This inventor holds 5 USPTO granted patents and 2 published patent applications and 2 EPO patents. Top assignee: Silver Creek Pharmaceuticals, Inc.. Active years: 2018-2024.

USPTO Granted Patents = 5 (Patent Applications = 2)

% Patents Active = 100.0

EPO Patents = 2 (Patent Applications = 3)

Average Co-Inventor Count = 8.0

ph-index = 3

Forward Citations = 12(Granted Patents)

Company Filing History:

5 out of 10

Silver Creek Pharmaceuticals, Inc.

patents

Years Active: 2018-2024

Loading Chart...

5 patents (USPTO):Sort by Forward CitationsExplore Patents

1. 12122819 - Method of treating skin tissue damage by topically administering a bi-specific protein comprising a human insulin-like growth factor variant and a human annexin A5 variant (2024-10-22),

2. 11879002 - Bi-specific therapeutic proteins, in vivo methods of use thereof and encoding nucleic acids thereof (2024-01-23),

3. 11155593 - Method of inhibiting apoptosis or promoting cell survival by providing a bi-specific protein comprising insulin-like growth factor IGF-1 and Annexin A5 (2021-10-26),

4. 10633425 - Method of protecting tissue from damage by administering a bi-specific therapeutic protein comprising insulin-like growth factor 1 (IGF-1) and Annexin A5 (2020-04-28),

5. 10040840 - Bi-specific annexin A5/IGF-1 proteins and methods of use thereof to promote regeneration and survival of tissue (2018-08-07),

Title: **Bjorn L Millard: Innovator in Bi-Specific Therapeutic Proteins**

Introduction

Bjorn L Millard is a distinguished inventor based in Orinda, CA, recognized for his significant contributions to the field of biotechnology. With a total of five patents to his name, Millard has focused on developing innovative solutions for treating skin tissue damage using advanced protein technologies.

Latest Patents

Millard's latest patents include groundbreaking methods designed to treat skin tissue damage by topically administering a bi-specific protein. This protein integrates a human insulin-like growth factor variant and a human annexin A5 variant, offering promising therapeutic avenues. His patents emphasize both the creation of bi-specific fusion proteins with therapeutic applications and the formulation of pharmaceutical compositions containing these proteins. These innovations provide methods to repair or regenerate damaged or diseased tissue, reflecting a profound potential impact on modern medicine.

Career Highlights

Bjorn L Millard is currently affiliated with Silver Creek Pharmaceuticals, a company renowned for its advancements in pharmaceutical development. His work there has allowed him to push the boundaries of what therapeutic proteins can achieve, further solidifying his role as a key player in the biotechnology industry.

Collaborations

Throughout his career, Millard has collaborated with notable colleagues including Laura D J Antipov and Shawdee Eshghi. These partnerships have enriched his research and development endeavors, fostering an environment of innovation and pioneering solutions in therapeutic protein applications.

Conclusion

Bjorn L Millard’s contributions to the field of biotechnology, particularly through his patented inventions, showcase his commitment to advancing medical treatments. His work in developing bi-specific therapeutic proteins exemplifies the potential of innovative research to transform healthcare outcomes for individuals with skin tissue damage and beyond.